| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | White GC 2nd | |
| Nielsen B | |||
| Beebe A | |||
| P433 | issue | 1 | |
| P304 | page(s) | 261-265 | |
| P577 | publication date | 1997-07-01 | |
| P1433 | published in | Thrombosis and Haemostasis | Q15724413 |
| P1476 | title | Recombinant factor IX | |
| P478 | volume | 78 |
| Q27012571 | Animal models of hemophilia |
| Q34348566 | BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B |
| Q47324534 | Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding. |
| Q36567954 | Chemical polysialylation of human recombinant butyrylcholinesterase delivers a long-acting bioscavenger for nerve agents in vivo. |
| Q37316242 | Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models |
| Q36099126 | Engineering protein processing of the mammary gland to produce abundant hemophilia B therapy in milk |
| Q27014771 | Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias |
| Q52663655 | Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway. |
| Q92899518 | Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity |
| Q42009729 | Improved expression of recombinant human factor IX by co-expression of GGCX, VKOR and furin |
| Q37591452 | Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs |
| Q26751323 | New developments in the management of moderate-to-severe hemophilia B |
| Q28078281 | Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B |
| Q34458349 | Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia |
| Q45876681 | Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis |
| Q58726516 | Prevention and Management of Bleeding Episodes in Children with Hemophilia |
| Q37634856 | Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide |
| Q35006603 | Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency |
| Q33589742 | Recent advances in haematology |
| Q35913495 | Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice |
| Q39171367 | Recombinant human butyrylcholinesterase as a new-age bioscavenger drug: development of the expression system |
| Q33736142 | Recombinant human factor IX produced from transgenic porcine milk |
| Q37357215 | Secondary prophylaxis with factor IX concentrates: continuous infusion. |
| Q30235127 | The History of Clotting Factor Concentrates Pharmacokinetics |
| Q36661548 | The effects of proton radiation on the prothrombin and partial thromboplastin times of irradiated ferrets |
| Q34329068 | Treatment of hemophilia B: focus on recombinant factor IX. |
Search more.